Navigation Links
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Date:8/20/2013

WOODCLIFF LAKE, N.J., Aug. 20, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) for bupropion hydrochloride (HCl) extended-release (ER) tablets USP (XL), 300 mg.  Bupropion HCl ER tablets USP (XL) is the generic version of WELLBUTRIN XL® and is indicated for the treatment of major depressive disorder (MDD).  Par's supply to the market of bupropion HCl ER tablets USP (XL), 150 mg and 300 mg, has been uninterrupted since originally approved in December 2006. 

In September 2012, FDA requested all generic drug companies marketing a version of bupropion HCl ER tablets, 300 mg, to conduct a fasting bioequivalence (BE) study comparing their bupropion HCl ER tablets, 300 mg, to GSK's WELLBUTRIN XL® (bupropion hydrochloride extended release) Tablets, 300 mg.  In December 2012, Par submitted a sANDA containing the requested study to FDA, which demonstrated in vivo bioequivalence of Par's bupropion HCl ER tablets USP (XL), 300 mg, to WELLBUTRIN XL® Tablets, 300 mg.  In April 2013, Par's sANDA was approved. 

Important Information About Bupropion HCl ER Tablets (XL) 
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a seizure disorder, in patients treated with ZYBAN® (bupropion hydrochloride extended-release tablets (XL)); WELLBUTRIN® (bupropion hydrochloride tablets), the immediate-release formulation; WELLBUTRIN SR® (bupropion hydrochloride extended-release tablets (SR)), the sustained-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent, in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ferring Pharmaceuticals Provides Baby Quest Foundation Grant Recipients with Free Access to Fertility Medication
2. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
3. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
4. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
5. TetraLogic Pharmaceuticals Announces New Executives
6. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
7. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
8. Pharmaceutical Companies Can Avoid Costly Launch Expenses by Leveraging and Pooling Sales and Promotional Resources
9. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
10. Japan Pharmaceutical Market Outlook
11. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Asia-Pacific Infusion Therapy Device Market ... Abstract: The Asia-Pacific ... infusion pumps, syringe infusion pumps, disposable infusion pumps, ... categories are segmented based on the type of ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Oct. 20 Premier Research Group Limited, the international ... of Bernard Sweeney as Executive Director, Medical Devices. In ... in the operations, strategic planning, and corporate development of ... will be based in Premier Research,s Swiss office. , ...
... 20 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Investor Conference at 11:30 a.m. Pacific Time on October ... San Diego, California. , ISTA,s Chief Financial Officer, Lauren ... and clinical progress. To access the live audio broadcast, ...
Cached Medicine Technology:Premier Research Names Bernard Sweeney as Executive Director, Medical Devices 2
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... Steven Reinberg HealthDay ... A device intended to help with weight loss by blocking ... meet expectations in a trial among obese patients. Using ... the brain and stomach, researchers hoped to suppress feelings of ... anticipated. "A device that safely blocks the nerve that ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... a few millimeters, depends on a supply of nutrients ... vascular wall cells of neighboring blood vessels to sprout ... blood circulation. , This process called angiogenesis involves ... receptors on the vascular wall cells. The departments of ...
... birds in the tropics look like they,re a drag to ... experiments by University of California, Berkeley, biologists shows that they ... at least in hummingbirds. , "We estimate that having a ... to 3 percent, which means the bird has to visit ...
... will help 5,000 more impoverished children in ... 2009 Best Picture "Slumdog Millionaire" shines the ... in India. Children International answers ... center to help poor children in Calcutta.To ...
... RALEIGH, N.C., March 12 MedThink Communications, a ... doctorate-level associate scientific director to support its rapidly ... two scientific directors at MedThink who provide high-level ... clients. With a team of seven doctorate-level medical ...
... study finds , , THURSDAY, March 12 (HealthDay News) ... testing athletes, because current tests ignore important ethnic ... and other hormones that increase testosterone levels are ... used in sports, according to the World Anti-Doping ...
... Highlights- Revenue: $35.7 million, up 19% from $29.9 million ... Q4,07LAWRENCE, Mass., March 12 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today reported financial results for the three ... included revenue and Adjusted EBITDA results above the top ...
Cached Medicine News:Health News:A new measure for the malignancy of melanoma 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:Photos: Children International Opens Center to Help Poor Children in India 2Health News:MedThink Hires Associate Scientific Director to Support Its Growing Health Care Clientele 2Health News:European Researchers Call for New Doping Standards 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 11
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: